Iluvien

Fluocinolone acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It delivers continuous anti‑inflammatory therapy to the retina for up to 36 months, reducing the need for repeated injections, and is indicated for diabetic macular edema in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established export capabilities to the European Union and other regulated markets, and adhering to stringent quality standards.

Iluvien (fluocinolone acetonide) is used to manage ocular inflammatory conditions, specifically diabetic macular edema, by delivering corticosteroid therapy directly to the retina. - Diabetic macular edema: reduces retinal swelling and stabilizes visual acuity. - Chronic diabetic macular edema: provides sustained drug release, decreasing need for repeat injections. - Refractory diabetic macular edema: offers an alternative when other therapies are insufficient.

Common Side Effects: - Increased intraocular pressure: may require topical medication. - Cataract formation: gradual lens opacity over time. - Ocular pain or discomfort after implantation. - Vitreous floaters: perception of moving spots. - Conjunctival hemorrhage: minor bleeding on the eye surface.

Serious or Rare Side Effects: - Endophthalmitis: severe intraocular infection. - Retinal detachment: separation of retinal layers. - Implant migration: displacement of the device within the eye. - Severe ocular hypertension: pressure rise needing surgical intervention. - Vision loss: irreversible loss of visual acuity.

Iluvien requires careful patient assessment and monitoring. - Patient selection: evaluate for pre‑existing glaucoma or uncontrolled intraocular pressure. - Monitoring: schedule regular intraocular pressure checks after implantation. - Contraindications: avoid in eyes with active infection or inflammation. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Systemic corticosteroid use: consider additive immunosuppressive effects. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Iluvien may interact with other ocular or systemic agents. Major Interactions (Avoid): - Other intravitreal corticosteroids: additive pressure rise. - Systemic potent CYP3A4 inhibitors: may increase systemic exposure. - Active ocular infection: contraindicated during implantation. Moderate Interactions (Monitor Closely): - Topical ocular NSAIDs: increased risk of corneal toxicity. - Systemic anticoagulants: monitor for ocular hemorrhage.